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Abstract 
 
Background  
Trisomy 18 and Smith Lemli Opitz syndrome are two polymalformative conditions in which a 
cholesterol defect has been noted. When they occur prenatally, they are associated with a 
decreased maternal unconjugated estriol (uE3) level. Cholesterol plays an essential role in the 
Sonic Hedgehog pathway, allowing Shh protein maturation leading to its maximal activity. 
Many malformations in these two syndromes occur in Shh dependent tissues. We thus sought 
to assess whether a cholesterol defect could affect the Shh pathway and explain some of the 
observed malformations. 
Materials and methods  
We selected 14 cases of trisomy 18 and 3 cases of SLO in which the maternal uE3 level was 
decreased and reported malformations were observed after fetopathological examination. We 
correlated the number of malformations with maternal uE3 level. We then carried out 
cholesterol concentrations in separate culture media consisting of trisomy 18, SLO and 
control amniocytes. Finally, we analyzed the Shh pathway by testing the gene expression of 
several Shh components: GLI transcription factors, BMP2, BMP4, TGFβ1, COL1A1 and 
COL1A2. 
Results and discussion  
There was an inverse correlation between phenotypic severity and maternal uE3 levels in SLO 
and trisomy 18. The cholesterol levels in the amniocyte culture media were correlated with 
maternal uE3 levels and were significantly lower in T18 and SLO amniocytes, reflecting 
cholesterol defects. There was an alteration in the Shh pathway since expression of several 
genes was decreased in T18 and SLO amniocytes. However, these cholesterol defects were 
not solely responsible for the altered Shh pathway and the malformations observed. 
 Introduction 
 
The Hedgehog (Hh) cell-cell signaling pathway is conserved in animals and has critical roles 
in embryonic development. Hedgehog proteins are secreted morphogens that are involved in 
many biological processes during embryonic development, and dysregulation of the pathway 
leads to several human diseases. It is expressed in many tissues, especially those of the brain 
and limbs. Hh signaling organizes pattern formation in the embryonic limbs, neural tube and 
other structures, and also functions postembryonically in homeostatic processes such as tissue 
maintenance and regeneration [1]. In the resting state of Hh signaling, the transcriptional 
output of the pathway is held back by the membrane protein Patched (Ptc), which inhibits the 
seven-spanner Smoothened (Smo). The Hh pathway is activated when the secreted protein Hh 
binds and inactivates Ptc, thus relieving the inhibition exerted on Smo, rendering it active. 
Active Smo signals to the cytoplasm, leading to activation of the zinc finger transcription 
factors, the Gli proteins (Gli1, 2 and 3) in vertebrates [2]. 
Gli1 and Gli2 act primarily as transcriptional activators, and Gli2 is the primary activator of 
Hh target genes in neural tube patterning [3]. Gli3 can act as either a transcriptional activator 
or, if proteolytically processed, as a transcriptional repressor that keeps target genes inactive 
in the absence of ligand. Hh activity promotes transcriptional activation of target genes in two 
ways: it promotes formation of Gli activators and it blocks the proteolytic processing event 
that creates the Gli3 repressor. 
Shh is required for normal patterning of the limbs, where it regulates growth, digit number, 
and antero-posterior polarity [4]. 
Maturation of Hh protein needs the posttranslational addition of palmitate and cholesterol 
which both play a role in protein activity. Cholesterol level may be decreased in several 
instances. Its level has been reported to be low in at least two congenital defects: trisomy 18 
and Smith-Lemli-Opitz syndrome [5,6]. 
Trisomy 18 is one of the most frequent aneuploidies found in 1/8 000 births. Presence of an 
extra chromosome 18 is responsible for a polymalformative syndrome in which facial 
anomalies such as microcephaly, dolichocephaly, cleft palate, congenital heart defects and 
limb anomalies may be found [7].  
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive syndrome characterized by 
multiple congenital anomalies (craniofacial, limb), intellectual deficit and behavioral 
problems. SLOS is due to an inborn error of cholesterol synthesis and is caused by mutations 
in the DHCR7 gene (11q13.4) leading to a deficiency in the enzyme 3-beta-hydroxysterol-
delta7 reductase that converts 7-dehydrocholesterol to cholesterol [8]. 
Both affections are characterized by an extremely low level of unconjugated estriol [3] 
measured in maternal serum during the 2
nd
 trimester of pregnancy, and it has been reported 
that individuals with either of these syndromes exhibit low cholesterolemia. 
The aim of this study is to determine whether a cholesterol deficit may be responsible for 
phenotypic anomalies observed in these two syndromes that depend on the Shh pathway, i.e. 
craniofacial and limb anomalies. We studied cholesterol levels and the Shh pathway in 14 
cultures of trisomic 18 amniocytes and 3 cultures of SLO amniocytes. 
 
 
 
 
 
 
Materials and methods 
 
Materials 
 
Among our cases of prenatal diagnoses, 12 cases of trisomy 18 and 3 cases of SLO were 
selected. Fetopathological examination was recorded for each case, and malformations were 
reported in Table I. The number of malformations was compared to maternal uE3 levels and 3 
controls per trisomy 18 were chosen according to their term. 
Amniocytes from these 60 cases were grown in RPMI® medium. 
 
Liquid chromatography associated with tandem mass spectrometry (LC/MSMS) 
There is only a tiny amount of cholesterol in the amniocyte culture medium, and the 
cholesterol originated by efflux from amniocytes is at very low level, so its dosage is 
impossible using biochemical or CPG/SM methods. It is only accessible using a more 
sensitive technique, liquid chromatography associated with tandem mass spectrometry 
(LC/MSMS) as a measurement technique LC/MSMS. 
A range of cholesterol levels was established in the culture medium (RPMI®) (6 
concentrations ranging from 0 to 50 µg/mL) to perform a comparative quantitative dosage. 
 
For each cell culture, the protein digests from both plasma and serum lipoprotein fractions 
were analyzed on an ion trap mass spectrometer interfaced with an autosampler through 
which samples were loaded onto a C18 capillary column (100 × 0.1 mm). The capillary 
column was packed in-house with 5 μm C18 RP particles (Phenomenex, Cheshire, UK). The 
solvents A and B, used for the chromatographic separation of peptides, were 5% acetonitrile 
in 0.1% formic acid and 95% acetonitrile in 0.1% formic acid, respectively. The protein 
digest, injected onto the microcapillary column, was separated at a rate of 150 μL/min in the 
following gradient conditions: 0-120 min 0-25% B, 120-180 min 25-75% B, 180-190 min 75-
100% B, 190-200 min 100% B, 215-300 min 100% A. 
Quantification was obtained through comparison with epicoprostanol used as an internal 
standard. 
 
Cholesterol levels in culture flasks 
 
Cholesterol levels were related to the amount of protein contained in flasks, made possible 
using the Bradford protein assay. It was expressed in µg/mL/g of protein and was performed 
for the 60 cultures. 
 
RNA isolation and real-time RT-PCR analysis 
 
Total RNA from the amniocyte cultures was extracted using Trizol (Invitrogen by Fisher 
Bioblock Scientific, Illkirch, France). After extraction, 1 μg of DNase-I–treated RNA was 
reverse transcribed into cDNA in the presence of oligodT and Moloney murine leukemia virus 
reverse transcriptase (Invitrogen). The reaction was carried out at 37°C for 1 h followed by a 
further 10-min step at 95°C. Amplification of the generated cDNA was performed by real-
time PCR in an Applied Biosystems SDS7000 apparatus with appropriate primers designed 
using Primer Express software. The relative mRNA level was calculated with the 2
−ΔΔCT
 
method.  
The following Shh pathway gene expressions were analyzed with this method: transcription 
factors GLI1, GLI2 and GLI3, and target genes expressed in facial and skeletal bone 
formation BMP2, BMP4, TGFß1 and collagen type I genes COL1A1 and COL1A2. Their 
expression was compared to GAPDH expression. 
 
 
Western blot analysis 
In order to confirm Shh pathway alteration, we performed Western blot analysis in trisomy 18 
amniocytes compared to control amniocytes for Shh proteins BMP2 and COL1A1. They were 
all compared with GAPDH expression. 
 
 
Treatment of control amniocytes with HMG-CoA reductase inhibitor 
Control amniocytes were treated with an inhibitor of HMG-CoA reductase (atorvastatin®) in 
order to deplete cholesterol levels in the amniocyte culture medium to the same level 
observed in trisomy 18 and SLO. 
Treatment was performed with 50 µL of 100 µM atorvastatin®. Culture medium was 
collected on day 1, day 2 and day3 after treatment. This allowed us to obtain a cholesterol 
level as low as that observed in the culture medium of trisomy 18 amniocytes. 
 
 
Results 
 
Inverse correlation between maternal uE3 levels and phenotypic severity in fetuses with 
SLO or trisomy 18. 
We observed that decreased maternal uE3 level was associated with a higher number of 
malformations observed in 12 fetuses exhibiting trisomy 18 and 3 fetuses with SLO. The 
mean number of malformations was significantly (p = 0.02) higher (5.1) when uE3 was below 
0.35 MoM than when it was higher (3.1 malformations). 
Facial/cerebral anomalies were more frequent when uE3 was low. The association of 
cerebral/facial anomalies with limb anomalies was present in 4 fetuses out of 6 (when 
maternal uE3 < 0.35 MoM) and 1 fetus out of 7 when maternal uE3 > 0.35 MoM (Figure 1). 
The lower maternal uE3 is most frequently associated with facial and limb anomalies.  
 
 
Cholesterol concentration can be measured in culture medium and correlated with 
maternal uE3 levels 
Cholesterol levels measured from LC/MSMS were related to the amount of protein present in 
culture flasks and the mean cholesterol level in our culture flasks was approximately 10 
µg/mL/g of protein. According to our dosages, we found that cholesterol level out of protein 
ratio did not vary throughout the pregnancy period (data not shown) and we showed a 
correlation between maternal uE3 levels and cholesterol levels in the culture medium 
containing either control cases or trisomic 18 or SLO amniocytes. Results showing this trend 
are reported in Figure 2. 
 
 
Cholesterol level is significantly decreased in trisomy 18 and SLO amniocytes compared 
to control amniocytes 
We analyzed the cholesterol level in relation to term of pregnancy and found no significant 
difference throughout pregnancy, indicating that this concentration is valid independent of 
pregnancy term. Mean cholesterol level for each group (SLO, trisomy 18 and control) is 
reported in Figure 3. We observed that cholesterol level in culture medium is significantly 
higher (p<0.05 and p<0.01 respectively) in controls (15.21 µg/mL/g) than in cases of trisomy 
18 (11.54 µg/mL/g) and SLO (6.52 µg/mL/g). 
 
 
Sonic Hedgehog pathway is altered in trisomy 18 and SLO amniocytes  
 
We reported an alteration in the Shh pathway using 2 different approaches. 
 
Comparative expression of different target genes in the Sonic Hedgehog pathway is shown in 
Figure 4. We observed that all Gli transcription factors have decreased expression in trisomy 
18 and SLO amniocytes compared to control amniocytes. Gli3 is specifically decreased in 
trisomy 18 amniocytes, whereas Gli1 is predominantly decreased in SLO amniocytes. 
Target gene expression of the Sonic Hedgehog pathway is significantly decreased in trisomy 
18 amniocytes compared to control amniocytes. Results are shown in Table II. 
 
Western blot analysis 
Western blot analysis in trisomy 18 amniocytes compared to control amniocytes for proteins 
Shh, BMP2 and COL1A1 confirmed decreased expression of these proteins in trisomy 18 
amniocytes (Figure 5). 
 
Cholesterol defects alone, induced by treatment, does not alter Shh pathway as observed 
in trisomy 18 and SLO 
After treating control amniocytes with an inhibitor of cholesterol synthesis, we tested these 
cells for alterations in the Shh pathway by performing RT-PCR analysis of the previously 
tested genes. Tests showed a trend towards decreased expression of these genes in treated 
amniocytes, but it was not as low as that observed in trisomy 18 or SLO amniocytes (Figure 
6). 
 
Discussion 
 
Maternal uE3 level is measured during the second trimester of pregnancy for trisomy 21 
screening. It is not only decreased in this affection, but also when fetuses carry trisomy 18 
[10] or Smith-Lemli-Opitz syndrome [9,11]. In our study, we observed an inverse correlation 
between maternal uE3 levels and phenotypic severity, with fetuses exhibiting SLO, as Kratz 
(1999) and Tint reported [12,13]. However, these findings also correlated with trisomy 18, as 
a low uE3 level was associated with fetuses exhibiting significantly more clinical findings 
after fetopathological examination. Therefore, phenotypic abnormalities seem to be more 
severe when the maternal uE3 level is below 0.35 MoM. 
The uE3 level is known to reflect fetal cholesterol biosynthesis. The association between SLO 
phenotypic severity and cholesterolemia has already been reported where severity is 
correlated to 7-DHCR residual activity [12]. However, this has never been described in T18 
pregnancies. It is well known that hypocholesterolemia is found in Smith-Lemli-Opitz 
syndrome due to an enzymatic defect in the cholesterol biosynthesis pathway (7-DHCR) [14]. 
Hypocholesterolemia is also present in rare cases of living trisomic 18 patients [11]. 
Unfortunately, no enzymatic defect has been reported in this aneuploidy, but 7-DHC level is 
low, indicating a possible block upstream. It would be of interest to establish a sterol profile 
in the case of trisomy 18 in order to determine a possible enzymatic block in cholesterol 
synthesis. In the different syndromes associated with an enzymatic defect in cholesterol 
biosynthesis, low cholesterol level alone is not sufficient to explain all the malformations 
observed. However, the possible toxic role of a precursor accumulation has been discussed 
[15]. 
Maternal apolipoprotein E (apoE) genotype also plays a role, as these apolipoproteins are 
involved in materno-fetal cholesterol transport [16], with maternal homozygous apoE2 
associated with more severely affected fetuses. Indeed, cholesterol intake from the mother 
may lower phenotypic severity. 
We analyzed the cholesterol level in an amniocyte culture medium, a study that has not yet 
been reported. It reflects the cellular cholesterol level released by efflux [17]. The amount of 
cholesterol is tiny, making it impossible to measure using automated biochemistry. We thus 
performed measurements using an assay technique with better sensitivity, i.e. LC/MSMS, 
allowing cholesterol detection at very low levels and unaffected by culture medium and color. 
We observed a disturbance in cholesterol biosynthesis in trisomic 18 amniocytes, which 
correlates with the uE3 level measured in maternal serum. This cholesterol level is lowered by 
30% in the cases of trisomy 18 and 60% in the cases of SLO, reflecting the more severe 
hypocholesterolemia observed in the cases of SLO. This difference may originate from a 
supply from another enzymatic pathway or more efficient materno-fetal cholesterol transport. 
A significant decrease in cholesterol level in amniocyte culture medium is associated with low 
maternal uE3 and reflects a disturbance in the fetal cholesterol biosynthesis pathway.  
The association of both cerebrofacial and limb abnormalities correlates to the maternal uE3 
level. Moreover, we showed that limb abnormalities were constant among patients with 
uE3<0.35 MoM. We thus may hypothesize that there is an impact of this cholesterol 
disturbance on these tissues. However, their embryogenesis depends highly on the Shh 
pathway which needs cholesterol for its maturation. Thus it is not surprising to observe these 
malformations as Shh expression is predominant in notochord, brain, ZPA and bowel [18]. 
 
The link between Hh signaling and cholesterol is well established, as posttranslational 
addition of cholesterol plays a fundamental role in Shh maturation, where it helps to define 
the maximal activity of this morphogen due to liposolubility. However, the mechanisms of 
signal disruption are still insufficiently understood and there are contradictions regarding the 
role of cholesterol in long range signaling, where cholesterol can play an essential role [19] or 
can be unnecessary [20,21]. We thus sought to assess the role of an altered Shh pathway in the 
pathogenicity of trisomy 18 and SLO, since many genes are Shh pathway targets, among them 
genes involved in brain and limb embryogenesis. 
 
We demonstrated a decrease in all Gli transcription factor expression, as reported by Gofflot 
[22] in a SLO animal model treated with a DHCR7 inhibitor, AY-9944, which showed a 
significant decrease in Shh pathway target genes. Similarly, we reported a significant decrease 
in BMP2 expression, underlining a direct link between Shh and BMP2, but without a 
significant decrease in BMP4 expression, which is preferentially involved in dorso-ventral 
limb patterning and not directly linked to Shh [23]. Gofflot et al. also described an imbalance 
in Ihh expression in the forming cartilage of a rat model treated with triparanol, an inhibitor of 
the 24-dehydrocholesterol reductase, leading to syndactyly, with Bmp2 participating to the 
programmed cell death in digit formation [24]. We also reported a decreased expression of 
more downstream genes, such as type 1 collagen. This was expected since this collagen type 
is a target of BMP2 and TGFβ1. Type 1 collagen is a fibril-forming collagen found in most 
connective tissues which is abundant in bone, cornea, dermis and tendon. Its role in 
embryogenesis is predominant in bone formation and palatal fusion [25], and we may 
hypothesize that an alteration in its expression may participate to the occurrence of cleft 
palate which exists in our 3 SLO cases and 2 out of our 14 T18 cases. TGFβ1 expression, an 
important proliferation factor, was also decreased, which may in part explain in utero growth 
retardation, present in our 3 SLO cases and 4 out of our 14 T18 cases. In addition, limb 
shortness seems to be associated with deficiency in cholesterol biosynthesis during embryonic 
development. 
We tested whether this pathway alteration was associated with cholesterol deficit by treating 
normal amniocytes with an inhibitor of cholesterol synthesis (Atorvastatin) and testing gene 
expression of previously altered genes. Treatment led to a decrease of the same magnitude as 
that observed in trisomy 18 and SLO. However, despite a trend towards decreased expression, 
it was not significant. We may hypothesize that this lack of treatment impact may either be 
due to a weak sensitivity of amniocytes to treatment, or insufficient treatment time, or a 
supply of other sterols in this in vitro model, or a combination of these events. Therefore, the 
cholesterol level decrease attributable to the treatment is not solely responsible for altered 
expression of downstream genes in the pathway. There is the need for other disturbing events 
to alter the pathway, which is similar to what Cooper et al. reported in an in vitro model of 
fibroblastic NIH3T3 cells. Compactin alone, an inhibitor of the HMG-CoA reductase, does 
not alter the pathway, whereas the addition of cyclodextrin, a cyclic oligosaccharide that 
depletes cells in cholesterol  and  affects Smo conformation does. However, they showed that 
pathway activation at the level of Gli1 was not affected, which is concordant with an effect on 
signal response and not its biogenesis demonstrating that this response also needs to be 
explored [6]. 
 
Using a different approach, we confirmed Shh pathway alteration in trisomy 18 as part of a 
decrease in Shh proteins BMP2 and COL1 expression in trisomic 18 amniocytes compared to 
normal amniocytes. Protein data clearly highlight Shh pathway alteration at different levels in 
trisomy 18 amniocytes. However, clear data on SLO amniocytes are lacking and further 
experiments are needed to address this question. 
 Finally, we demonstrated Shh pathway alteration in both trisomy 18 and SLO amniocytes 
using different approaches. This alteration may in part be due to a cholesterol defect, but other 
events are involved in this disturbance, and need to be explored. 
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 Table 1.  
Number of malformations observed in 12 cases of trisomy 18 (white) and 3 cases of SLO (gray) after fetopathological examination. 
NTD: neural tube defect, CHD: congenital heart defect, VSD: ventricular septal defect, malf: malformations MoM: multiple of median. 
 
 
 
 
 
   
Transcription factors 
 
TGFβ1 
 
Morphogenesis genes 
  
SHH 
 
GLI1 
 
GLI2 
 
GLI3 
 
TGFβ1 
 
COL1A1 
 
COL1A2 
 
BMP2 
 
BMP4 
 
T18 (10) 
 
= 
 
↓↓ 
 
↓ 
 
↓↓↓ 
 
↓↓ 
 
↓ 
 
↓↓ 
 
↓ 
 
= 
 
SLO (3) 
 
NA 
 
↓↓↓ 
 
↓ 
 
↓ 
 
↓ 
 
↓↓ 
 
↓ 
 
↓↓ 
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Table II 
Comparative expression of Gli transcription factors and Shh target genes in trisomy 18 (n : 10) and SLO (n : 3) cases compared to 8 control cases. NA : not 
available 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1 
Facial and/or limb abnormalities were recorded in comparison to maternal uE3 levels (< 0.35 MoM in grey, and > 0.35 MoM in white). MoM : multiple of 
median. When maternal uE3 level is below 0.35 MoM, limb abnormalities are constant and the association of facial and limb abnormalities is much more 
predominant. 
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Figure 2 
Cholesterol/protein ratios were compared to maternal uE3 levels measured during pregnancy in the 3 different groups analyzed (control, trisomy 18 and SLO 
cases). There is a correlation between cholesterol/protein ratios measured in amniocytes culture medium compared to maternal uE3 level. This trend is 
indicated through the black line (parametric Pearson’s test, p<0.05). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3 
Cholesterol/protein ratios in the 3 different groups: control group (n=45), trisomy 18 group (n=12) and SLO (n=3). This ratio is expressed in µg/mL/g  protein. 
It is significantly decreased in T18 and SLO groups, compared to control group. Statistical significance was evaluated using the Student’s t-test (* :p<0.05) 
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Figure 4 
Comparative expression of different Shh pathway genes in T18 and SLO amniocytes, compared to control amniocytes. The expression is in arbitrary units 
with GAPDH as reference gene (1). Total RNAs were extracted from amniocytes and 1 µg was reverse-transcribed into cDNA. The resulting products were 
diluted (1/100) and analyzed by real-time PCR using specific primers for GLI1, GLI2, GLI3, TGFβ1, COL1A1, COL1A2, BMP2 and BMP4. Results were 
normalized to GAPDH cDNA. The expression shown is the average of 3 experiments. 8 control cases, 10 trisomy 18 cases and 3 SLO cases were analyzed. 
Statistical significance was evaluated using Student’s t-test (* : p<0.05 ; ** : p<0.01 ; *** : p<0.001) 
 
 
 
 
 
 Fig. 5.  
SHH, BMP2 and COL1A1 expressions are decreased in T18 amniocytes compared to control amniocytes. 
15 μg of nuclear extracts from T18 or control amniocytes was separated on a 10% polyacrylamide gel in denaturing conditions. Then, proteins 
were transferred to a PVDF membrane and immuno-blotted with polyclonal antibodies directed against SHH (A, B), BMP2 (C, D) and COL1A1 
(E) and GAPDH as loading control. After washing with TBS-T, PVDF membranes were incubated with the appropriate secondary antibody and 
proteins were revealed with the super signal West-Pico® detection kit. 
  
Figure 6 
Comparative expression of different Shh pathway’s genes in control amniocytes, after 3 (D3) or 6 days (D6) of treatment with an anti-cholesterol. The 
expression isin arbitrary unit with GAPDH as reference gene (1). Total RNAs were extracted from amniocytes and 1 µg was reverse-transcribed into cDNA. 
The resulting products were diluted (1/100) and analyzed by real-time PCR using specific primers for GLI1, GLI2, GLI3, TGFβ1, COL1A1, COL1A2, BMP2 
and BMP4. Results were normalized to GAPDH cDNA without treatment. The expression shown is the average of 3 experiments. We analyzed 3 cases at D3, 
and 5 cases at D6. Statistical significance was evaluated using the Student’s t-test (* : p<0.05 ; ** : p<0.01 ; *** : p<0.001) 
 
 
